Ibrutinib

FDA Approved: * March 31, 2021
Pharm Company: * ZYDUS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ibrutinib Overview

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.[4][5]...

Read more Ibrutinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ibrutinib

Recent Ibrutinib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ibrutinib
  • Capsule: 140 Mg., 140mg, 70mg
  • Tablet: 140mg, 280mg, 420mg, 560mg
  • Unknown: Unknown
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Ibrutinib or a similar ingredient: (1 result)